These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39428978)

  • 1. Bioactive metabolites: a clue to the link between MASLD and CKD?
    Chen WY; Zhang JH; Chen LL; Byrne CD; Targher G; Luo L; Ni Y; Zheng MH; Sun DQ
    Clin Mol Hepatol; 2024 Oct; ():. PubMed ID: 39428978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Microbiota-Related Co-Metabolites in MASLD Progression: A Narrative Review.
    Martin-Grau M; Monleón D
    Curr Issues Mol Biol; 2024 Jun; 46(7):6377-6389. PubMed ID: 39057023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.
    Lai J; Luo L; Zhou T; Feng X; Ye J; Zhong B
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759756
    [No Abstract]   [Full Text] [Related]  

  • 4. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.
    Lu X; Yang R; Chen Y; Chen D
    iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease.
    Long Q; Luo F; Li B; Li Z; Guo Z; Chen Z; Wu W; Hu M
    Hepatol Commun; 2024 Mar; 8(3):. PubMed ID: 38407327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.
    Lavelle A; Sokol H
    Nat Rev Gastroenterol Hepatol; 2020 Apr; 17(4):223-237. PubMed ID: 32076145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment.
    Zhang R; Yan Z; Zhong H; Luo R; Liu W; Xiong S; Liu Q; Liu M
    Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38967596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.
    Jaeger JW; Brandt A; Gui W; Yergaliyev T; Hernández-Arriaga A; Muthu MM; Edlund K; Elashy A; Molinaro A; Möckel D; Sarges J; Halibasic E; Trauner M; Kahles F; Rolle-Kampczyk U; Hengstler J; Schneider CV; Lammers T; Marschall HU; von Bergen M; Camarinha-Silva A; Bergheim I; Trautwein C; Schneider KM
    JHEP Rep; 2024 Mar; 6(3):100987. PubMed ID: 38328439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary glycation compounds - implications for human health.
    Hellwig M; Diel P; Eisenbrand G; Grune T; Guth S; Henle T; Humpf HU; Joost HG; Marko D; Raupbach J; Roth A; Vieths S; Mally A
    Crit Rev Toxicol; 2024 Sep; 54(8):485-617. PubMed ID: 39150724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics.
    Yuan H; Jung ES; Chae SW; Jung SJ; Daily JW; Park S
    Nutrients; 2024 Sep; 16(18):. PubMed ID: 39339660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction-associated steatotic liver disease: a comprehensive review.
    Ku JL; Hsu JR; Li YT; Wu LL
    J Gastroenterol Hepatol; 2024 Sep; ():. PubMed ID: 39343617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α.
    Hai S; Li X; Xie E; Wu W; Gao Q; Yu B; Hu J; Xu F; Zheng X; Zhang BH; Wu D; Yan W; Ning Q; Wang X
    Hepatology; 2024 Jul; ():. PubMed ID: 38985971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota-NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease.
    Yu T; Luo L; Xue J; Tang W; Wu X; Yang F
    Clin Res Hepatol Gastroenterol; 2024 Oct; 48(8):102458. PubMed ID: 39233138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.
    Ha S; Wong VW; Zhang X; Yu J
    Gut; 2024 Dec; 74(1):141-152. PubMed ID: 38950910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of metabolites derived from gut microbiota in inflammatory bowel disease.
    Zheng L; Wen XL; Duan SL
    World J Clin Cases; 2022 Mar; 10(9):2660-2677. PubMed ID: 35434116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8
    Zheng C; Wang L; Zou T; Lian S; Luo J; Lu Y; Hao H; Xu Y; Xiang Y; Zhang X; Xu G; Zou X; Jiang R
    J Hepatol; 2024 May; 80(5):764-777. PubMed ID: 38181823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Zazueta A; Valenzuela-Pérez L; Ortiz-López N; Pinto-León A; Torres V; Guiñez D; Aliaga N; Merino P; Sandoval A; Covarrubias N; Pérez de Arce E; Cattaneo M; Urzúa A; Roblero JP; Poniachik J; Gotteland M; Magne F; Beltrán CJ
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lupeol improves bile acid metabolism and metabolic dysfunction-associated steatotic liver disease in mice via FXR signaling pathway and gut-liver axis.
    Qin D; Pan P; Lyu B; Chen W; Gao Y
    Biomed Pharmacother; 2024 Aug; 177():116942. PubMed ID: 38889641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.